Fracture of Foot Clinical Trial
Official title:
A Radiographic and Clinical Outcomes Study Evaluating map3® Cellular Allogeneic Bone Graft in Patients Undergoing Bone Grafting in the Foot/Ankle
Verified date | February 2015 |
Source | RTI Surgical |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle. Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells. This cohort study will enroll 24 patients total at 1 site. After subjects have signed an informed consent, the baseline visit and examinations will be completed. Patients will be evaluated at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months after surgery.
Status | Terminated |
Enrollment | 1 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Study subjects will be limited to patients with foot/ankle pathologies requiring fusion, which include midfoot, hindfoot, ankle, double and triple arthrodesis using open surgical technique with supplemental bone graft substitute. - Life expectancy of at least twenty four (24) months - Ability to give written informed consent - All subjects will have a minimum age of eighteen (18) years and a maximum of eighty (80) years. - Both male and non-pregnant female subjects will be included. - To facilitate follow-up, study subjects will be limited to the local geographic area of the study site and must be willing to use the rehabilitation facility and physical therapy schedule assigned by the surgeon. - All subjects must be able to read, write, and comprehend instructions and guidelines in English and understand (and sign as an acknowledgment of their understanding) an informed consent declaration Exclusion Criteria: - Patients who have been diagnosed with Charcot foot - Patients requiring osteotomies or undergoing a revision surgery for non-union - Patients with additional lower limb injuries requiring concomitant procedures not related to the current foot/ankle procedure - Patients with soft tissue compromise involving open and/or infected wounds on the study limb - Patients requiring any other bone grafting product other than study product (map3® Cellular Allogeneic Bone Graft) e.g. rhBMP2 (recombinant human bone morphogenetic protein 2). - Patients with confirmed diagnosis of abnormal lower limb vasculature or peripheral vascular disease - Patients with a high Body Mass Index ( BMI > 35) - Diagnosis of osteonecrosis, metabolic bone diseases or gout - Diabetic patients who are insulin dependent - Patients who have received any treatment within the past 12 months which may interfere with bone metabolism (bisphosphonates and/or calcitonin). - Patients using glucocorticoids > 10 mg/day - Chronic use (= 90 days) of non-steroidal anti-inflammatory drugs (NSAIDS) - Patients with active cancer or a history of any cancer - Known allergies to Dimethyl Sulfoxide (DMSO) and/or Human Serum Albumin (HSA) - Pregnant or lactating females or who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study - Patients who have tested positive for HTLV, HIV, hepatitis B or hepatitis C, have rheumatoid arthritis, an autoimmune disease or are on chronic immunosuppressive medications - Require chronic use (= 90 days) of anticoagulation therapy - Active smokers unwilling to comply with surgeons instructions to stop smoking seven (7) days prior to surgery through three (3) month post-op visit - History of alcohol or drug abuse within 90 days of screening - Patients currently enrolled or have been enrolled in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 90 days of enrollment. - Patients unable to give written informed consent and any vulnerable patient population - Inability to comply with all requirements of this investigation, as well as follow the instructions of the physician |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Saint Francis Hospital | Roslyn | New York |
Lead Sponsor | Collaborator |
---|---|
RTI Surgical |
United States,
Clements JR. Use of allograft cellular bone matrix in multistage talectomy with tibiocalcaneal arthrodesis: a case report. J Foot Ankle Surg. 2012 Jan-Feb;51(1):83-6. doi: 10.1053/j.jfas.2011.09.002. Epub 2011 Oct 20. — View Citation
Guyton GP, Miller SD. Stem cells in bone grafting: Trinity allograft with stem cells and collagen/beta-tricalcium phosphate with concentrated bone marrow aspirate. Foot Ankle Clin. 2010 Dec;15(4):611-9. doi: 10.1016/j.fcl.2010.09.003. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Time to Full Weight-bearing | This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks. | up to 24 months | No |
Primary | AOFAS Foot-and-Ankle Score | The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery. | 24 months | No |
Secondary | SF-36 Score | The SF-36 is a survey for health and well-being. | 24 months | No |
Secondary | Foot Ankle Disability Index | The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100. | 24 months | No |
Secondary | CT Scan | A CT scan will be done at 6 months in order to assess bone fusion. | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05555459 -
Performance and Safety Evaluation of Inion CompressOn Screw in Foot and Ankle Surgeries. PMCF Investigation
|
N/A | |
Not yet recruiting |
NCT05844280 -
The Role of Blood Flow Restriction Therapy in Postop Rehabilitation of Foot and Ankle Injuries
|
N/A |